Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, PLW

Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office

US Patent 11,369,618 Issued on June 28, 2022

HADDONFIELD, N.J., Sept. 21, 2022 /PRNewswire/ -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on June 28, 2022 the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,369,618 ('618 patent) entitled "Compounds, Compositions Methods for Prevention and/or Treatment of Cancer".

The '618 patent covers the use of the company's lead compound, LNS8801 and other G-protein estrogen receptor (GPER) agonists in combination with various therapies, including anti-PD-1/L1 therapies, to prevent or treat GPER-expressing cancers.

"We are extremely pleased that the USPTO has issued this critical patent, the third essential patent in our GPER agonist patent portfolio," commented Patrick Mooney, MD, CEO of Linnaeus. "We believe that the issued claims will provide critical market protection for LNS8801 through at least 2037. As we continue to collect very promising data from our clinical trials of LNS8001, we plan to prosecute the '618 patent on a worldwide basis."

Linnaeus is testing LNS8801 in its phase 1/2 adaptive-design clinical trial as a monotherapy and in combination with pembrolizumab in patients who had previous clinical benefit from immune checkpoint inhibitors and then subsequently progressed.

About LNS8801

LNS8801 is an orally bioavailable and highly specific and potent agonist of GPER whose activity is dependent on the expression of GPER. GPER activation by LNS8801 rapidly and durably depletes c-Myc protein levels. In preclinical cancer models, LNS8801 displays potent antitumor activities across a wide range of tumor types, rapidly shrinking tumors and inducing immune memory.

In the ongoing clinical study in humans, LNS8801 monotherapy has been safe and well tolerated. Additionally, LNS8801 has demonstrated target engagement, c-Myc protein depletion, and clinical benefit in patients with advanced cancers.

About Linnaeus

Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics that target G protein-coupled receptors. The company was formed and launched in partnership with the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI).

SOURCE Linnaeus Therapeutics, Inc.

These press releases may also interest you

at 12:55
VERSES AI Inc. (CBOE CANADA:VERS) ("VERSES'' or the "Company"), a cognitive computing company specializing in the next generation of artificial intelligence ("AI"), announces the release in June 2023 of an AI industry report titled "THE ROAD TO...

at 12:55
Cloverleaf Analytics (Cloverleaf), the leading provider of insurance intelligence solutions, announced today at the DigIn 2023 Conference in San Francisco that Citizens United Reciprocal Exchange (CURE) Auto Insurance is now live on Cloverleaf across...

at 12:50
DEEPX, an industry-leading artificial intelligence semiconductor technology company, today announced that the company has received Vision System Design Magazine's Innovation Virtual 2023 Gold Medal. This recognition confirms that DEEPX's Neural...

at 12:45
LinkSquares, the leading AI-powered legal technology partner of choice, announced today that it was among the select companies that Forrester invited to participate in The Forrester Wavetm: Contract Lifecycle Management, Q2 2023 report. In this...

at 12:35
Project Management Institute (PMI), the world's leading organization for the project management profession, today announced the publication of a new book of thought leadership from their Brightline® initiative. Completed in partnership with...

at 12:35
CPSI , a healthcare solutions company, today announced that Chris Fowler, President and Chief Executive Officer, and Matt Chambless, Chief Financial Officer, will participate in the Stifel 2023 Cross Sector Insight Conference being held June 6-7,...

News published on and distributed by: